Posted by ABMN Staff on May 19th, 2024
Truist Financial reissued their buy rating on shares of Curis (NASDAQ:CRIS – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. Truist Financial currently has a $26.00 target price on the biotechnology...
More of this article »